Literature DB >> 26058730

Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial.

M Ozelo1, M Misgav2, F Abdul Karim3, S R Lentz4, M Martin-Salces5, I Matytsina6, T Saugstrup6, E Santagostino7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26058730     DOI： 10.1111/hae.12737

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  2 in total

1.  Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model.

Authors:  Andreas Tiede; Faraizah Abdul Karim; Victor Jiménez-Yuste; Robert Klamroth; Sandra Lejniece; Takashi Suzuki; Andreas Groth; Elena Santagostino
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

Review 2.  Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration.

Authors:  Kanecia O Zimmerman; P Brian Smith; Ann W McMahon; Jean Temeck; Debbie Avant; Dianne Murphy; Susan McCune
Journal:  JAMA Pediatr       Date:  2019-01-01       Impact factor: 26.796
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.